Outcomes Assessment following Treatment of Spasmodic Dysphonia with Botulinum Toxin
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Spasmodic dysphonia (SD), a disabling focal dystonia involving the laryngeal musculature, is most commonly treated by the intramuscular injection of botulinum toxin (BTX). Although the treatment is well tolerated and generally produces clinical voice improvement, it has never been statistically shown to alter the patient's perception of voice quality or general health. Declining resources for medical care mandate that treatment outcomes be documented. A prospective analysis of the effects of BTX on the patient's perception of voice and general health was undertaken. The Voice Handicap Index (VHI) and Short Form 36 (SF-36) surveys were administered to patients before treatment and 1 month after. Pretreatment and posttreatment scores were analyzed with a Student's t-test. On the VHI, improvements in the patients' perception of their functional, physical, and emotional voice handicap reached statistical significance (p < or = .0005). On the SF-36, patients had statistically significant improvements in mental health (p < or = .03) and social functioning (p < or = .04). Treatment of SD with BTX significantly lessened the patients' perception of dysphonia. In addition, it improved their social functioning and their perception of their mental health. These outcome measures justify the continued treatment of SD with BTX.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have also explored the psychosocial impact of SD using more general health-related questionnaires that do not focus specifically on communication disorders”
From The consequences of spasmodic dysphonia on communication-related quality of life: A qualitative study of the insider's experiences (2005) · cites this paper as Courey et al., 2000
In the citing paper
“However, more recent investigations that explore the psychosocial impact of SD have been conducted using scales designed specifically for voice disorders including the Voice Handicap Index (VHI)”
From The consequences of spasmodic dysphonia on communication-related quality of life: A qualitative study of the insider's experiences (2005) · cites this paper as Courey et al., 2000
In the citing paper
“Elevated symptoms of anxiety, depression and other negative affective responses to SD have been documented in other studies using a variety of health-related instruments (Cannito, 1991; Cannito et al., 1994; Courey et al., 2000; Langeveld, Luteijn et al., 2001; Liu et al., 1998; Murry et al., 1994).”
From The consequences of spasmodic dysphonia on communication-related quality of life: A qualitative study of the insider's experiences (2005) · cites this paper as Courey et al., 2000
In the citing paper
“The contribution of effort and fatigue to the psychosocial consequences of SD may be captured in the VHI (Benninger et al., 2001; Courey et al., 2000) and V-RQOL (Hogikyan et al., 2001; Rubin et al., 2004) because each scale contains questions addressing these symptoms.”
From The consequences of spasmodic dysphonia on communication-related quality of life: A qualitative study of the insider's experiences (2005) · cites this paper as Courey et al., 2000
In the citing paper
“Although existing voice-related instruments document psychosocial consequences of SD (Benninger et al., 2001; Courey et al., 2000; Hogikyan et al., 2001; Rubin et al., 2004), results from the present study, based on the insider's perspective, suggest that there is still room for further work in this area.”
From The consequences of spasmodic dysphonia on communication-related quality of life: A qualitative study of the insider's experiences (2005) · cites this paper as Courey et al., 2000
Citations
Cites
The Voice Handicap Index (VHI): Development and Validation
Jacobson, B. H., Johnson, A., Grywalski, C., Silbergleit, A., Jacobson, G., Benninger, M. S., & Newman, C. W. (1997) · American Journal of Speech-Language Pathology · doi:10.1044/1058-0360.0603.66 · Cited by 2,574
Epidemiology of focal and generalized dystonia in Rochester, Minnesota
Nutt, J. G., Muenter, M. D., Aronson, A., Kurland, L. T., & Melton, L. J. (1988) · Movement Disorders · doi:10.1002/mds.870030302 · Cited by 480
Rivner, M. H. (1995) · Neurology · doi:10.1212/wnl.45.6.1244-a · Cited by 280
Blitzer, A., Brin, M. F., Fahn, S., & Lovelace, R. E. (1988) · The Laryngoscope · doi:10.1288/00005537-198802000-00015 · Cited by 260
Clinical and laboratory characteristics of focal laryngeal dystonia: Study of 110 cases
Dds, A. B., Briny, M. F., Fahn, S., & Lovelace, R. E. (1988) · The Laryngoscope · doi:10.1288/00005537-198806000-00012 · Cited by 159
Intermediate results of 306 recurrent laryngeal nerve sections for spastic dysphonia
Dedo, H. H., & Izdebski, K. (1983) · The Laryngoscope · doi:10.1288/00005537-198301000-00002 · Cited by 71
Long-Term Follow-up of Recurrent Laryngeal Nerve Avulsion for the Treatment of Spastic Dysphonia
Jewett, B. S., Stone, R. E., Weed, D. T., Rainey, C. L., Ossoff, R. H., Zealear, D. L., & Netterville, J. L. (1996) · Annals of Otology Rhinology & Laryngology · doi:10.1177/000348949610500802 · Cited by 50
Self-citationAlternating Unilateral Botulinum Toxin Type A (BOTOX®) Injections for Spasmodic Dysphonia
Koriwchak, M. J., Netterville, J. L., Snowden, T., Courey, M. S., & Ossoff, R. H. (1996) · The Laryngoscope · doi:10.1097/00005537-199612000-00006 · Cited by 30
Self-citationThe larynx: a multidisciplinary approach
Drake‐Lee, A. (1990) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/0266-4356(90)90026-h · Cited by 6
Research works printed but not linked: 3
- Ludlow CL, 1994, Therapy with botulinum toxin, 437
- Schantz EJ, 1994, Therapy with botulinum toxin, xxii
- Ware JE, 1993, SF-36 Health Survey manual & interpretation guide
Cited by
Clinical Practice Guideline: Hoarseness (Dysphonia)
Schwartz, S. R., Cohen, S. M., Dailey, S. H., Rosenfeld, R. M., Deutsch, E. S., Gillespie, M. B., Granieri, E., Hapner, E. R., Kimball, C. E., Krouse, H. J., et al. (2009) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2009.06.744 · Cited by 453
Botulinum toxin in clinical practice
Jankovic, J. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034702 · Cited by 408
Clinical Practice Guideline: Hoarseness (Dysphonia) (Update)
Stachler, R. J., Francis, D. O., Schwartz, S. R., Damask, C. C., Digoy, G. P., Krouse, H. J., McCoy, S. J., Ouellette, D. R., Patel, R. R., Reavis, C. (. W., et al. (2018) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599817751030 · Cited by 368
“Botulinum toxin treatment has also been shown to improve self-perceived dysphonia, mental health, and social functioning.(408) A meta-analysis concluded that botulinum toxin treatment of SD results in “moderate overall improvement”; however, it noted concerns of methodological limitations and lack of standardization i…”
BackgroundJankovic, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70574-9 · Cited by 332
Quality-of-Life Impact of Non-Neoplastic Voice Disorders: A Meta-Analysis
Cohen, S. M., Dupont, W. D., & Courey, M. S. (2006) · Annals of Otology, Rhinology & Laryngology · doi:10.1177/000348940611500209 · Cited by 258
Self-citation
Metadata
- Authors
- Courey, M. S., Garrett, C. G., Portell, M. D., Billante, C. R., Smith, T. L., Stone, R. E., & Netterville, J. L.
- Affiliations
- Nashville, Tennessee
- Milwaukee, Wisconsin
- Venue
- Annals of Otology, Rhinology & Laryngology
- Publisher
- SAGE Publications
- Published
- 2000-09
- Volume
- 109
- Issue
- 9
- Pages
- 819-822
- ISSN
- 0003-4894 (ISSN-L)
- 1943-572X
- OpenAlex
- W2332816826
- Cited by
- 70
- References
- 9
- Citations by year
- 2026: 3 · 2025: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2018: 5 · 2017: 1 · 2016: 2 · 2015: 3 · 2013: 4 · 2012: 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Otology Rhinology & Laryngology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Health Professions › Speech and Hearing › Voice and Speech Disorders
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- spasmodic dysphonia, botulinum toxin, focal dystonia, Voice Handicap Index, SF-36, voice handicap, quality of life, mental health, social functioning, treatment outcomes
- MeSH terms
- Adult, Aged, Botulinum Toxins, Female, Humans, Laryngeal Muscles, Male, Middle Aged, Neuromuscular Agents, Prospective Studies, Surveys and Questionnaires, Severity of Illness Index, Spasm, Voice Disorders, Voice Quality, Treatment Outcome, Patient Satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes Assessment following Treatment of Spasmodic Dysphonia with Botulinum Toxin. https://app.cochat.ai/papers/10.1177/000348940010900906
- The paper
- Courey, M. S., Garrett, C. G., Portell, M. D., Billante, C. R., Smith, T. L., Stone, R. E., & Netterville, J. L. (2000). Outcomes Assessment following Treatment of Spasmodic Dysphonia with Botulinum Toxin. Annals of Otology, Rhinology & Laryngology. https://doi.org/10.1177/000348940010900906
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.